Published on: Feb 10, 2026
The United States is rapidly becoming an older nation. By 2050, nearly one in four Americans will be 65 or older, many living into their 90s. While longer life expectancy reflects medical progress, it also raises concerns about healthcare demands and, more importantly, quality of life in later years.
A major contributor to age-related decline is chronic, low-grade inflammation often called “inflammaging” which weakens immunity and increases vulnerability to conditions such as arthritis, bone loss, fatigue, and frailty.
In a recent six-year NIH-funded study, Keith Kirkwood and his team investigated tristetraprolin (TTP), an RNA-binding protein that suppresses inflammation. Because TTP levels decrease with age, inflammation rises. By genetically stabilizing TTP in elderly mice, researchers observed improved grip strength, endurance, bone health, and overall lower frailty scores. The findings, published in Aging and Disease (January 2026), suggest that enhancing TTP activity may promote healthier aging.
Although human applications remain distant, the study highlights TTP as a promising target for reducing age-related frailty and potentially addressing neuroinflammatory conditions such as dementia and Alzheimer’s disease.
Source: https://www.buffalo.edu/ubnow/stories/2026/02/kirkwood-anti-aging.html
Back to News
Empowering Innovation Through Global Conferences and Events.
© 2025 SciInov. All Rights Reserved.